HealthMore in Health→
Factor IX Padua AAV Gene Therapy Tested in Adolescents With Hemophilia B
Key Takeaways
- Nature Medicine published a phase 1 trial of an AAV gene therapy carrying the factor IX Padua variant in adolescents with hemophilia B.
- The study is described as single-arm phase 1, with the published summary reporting the therapy was well tolerated.
- The Padua variant is used for its higher clotting potency, which may allow therapeutic benefit at lower expression levels or vector doses.
- AAV vectors are the standard delivery platform for hemophilia gene therapy but carry immune-response considerations that trials monitor.
DE
DT Editorial Team··via nature.com